MIRXES-B公布2025年中期业绩，收益为1050万美元，同比增长9.4%。公司权益股东应占亏损约为 2835.23万美元，同比收窄36.22%，每股亏损0.185美元。收益增长主要归因于GASTROClear及 LUNGClear的收益增加。 （文章来源：证券时报网） ...

公告称，收益同比增加主要是由于早期检测及精準多组学分部的GASTROClearTM及LUNGClearTM产 生的收益增加，抵销了因终止FortitudeTM产品销售而导致的传染病分部收益减少260万美元。 MIRXES-B(02629)公布2025年中期业绩，收益为1050万美元，同比增加9.4%。公司权益股东应占亏损 约2835.23万美元，同比收窄36.22%;每股亏损0.185美元。 ...

公告称，收益同比增加主要是由于早期检测及精準多组学分部的 GASTROClear及LUNGClear产生的收 益增加，抵销了因终止Fortitude产品销售而导致的传染病分部收益减少260万美元。 智通财经APP讯，MIRXES-B(02629)公布2025年中期业绩，收益为1050万美元，同比增加9.4%。 公司 权益股东应占亏损约2835.23万美元，同比收窄36.22%;每股亏损0.185美元。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或依 賴該等內容而引致的任何損失承擔任何責任。 Mirxes Holding Company Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 責 任 公 司 ） （股份代號：2629） 截至2025年6月30日止六個月的 中期業績公告 Mirxes Holding Company Limited（「本公司」，連同其附屬公司，統稱「本集團」或 「我們」）董事（「董事」）會（「董事會」）宣佈本集團截至2025年6月30日止六個月 （「報告期」）的未經審核綜合業績，連同2024年同期的比較數字。 財務概要 – 1 – ‧ 截至2025年6月30日止六個月的收益為10.5百萬美元，與2024年同期的9.6 百萬美元相比增加9.4%。 ‧ 截至2025年6月30日止六個月，早期檢測及精準多組學分部的收益為 10.5百萬美元，較2024年同期的7.0百萬美元增長50%。 ‧ 截至2025年6月30日止六個月的毛利為7.1百萬美元，而2024年同期 ...

新加坡微小核糖核酸(miRNA)技术公司MIRXES-B(2629.HK)今日盘中一度涨8.1%至47.8港元，股价创上市新高，市值约132亿港元。该股于今年5月23日登陆 港交所，上市迄今不到3个月，现价较发行价23.3港元已累涨105%。 MIRXES-B公告，公司间接全资附属公司MiRXESPTE. LTD.近期已与PT DIASTIKA BIOTEKINDO(一间于印尼证券交易所上市的公司)订立一份谅解备忘 录，据此，双方同意在印尼进行用于高发病率及高死亡率癌症早期检测及诊断的分子诊断检测及相关仪器的注册及商业化方面进行合作。谅解备忘录期限自 签署日期起计为期12个月。董事会相信订立谅解备忘录乃集团推动全球化策略并将业务扩张至高潜力新兴市场的关键举措。(格隆汇) ...

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, reaching a new high of 47.8 HKD, driven by a strategic partnership with PT DIASTIKA BIOTEKINDO for cancer diagnostics in Indonesia [1][2] Group 1: Partnership and Market Expansion - The company has signed a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] - This partnership allows the company to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics cancer detection devices [2] - The collaboration aims to utilize local policies in Indonesia, such as tax incentives for local content, and regulatory flexibility under ASEAN medical device frameworks to facilitate market entry [2] Group 2: Regional and Global Strategy - Indonesia is positioned as a pilot region for the company's operations, with plans to replicate the business model in Southeast Asia, the Middle East, North Africa, and other regions that share similar cancer profiles and healthcare structures [2]

Core Viewpoint - MIRXES-B (02629) has seen a significant increase in stock price, rising over 8% to reach a new high of 47.8 HKD, following the announcement of a memorandum of understanding with PT DIASTIKA BIOTEKINDO for collaboration in the Indonesian market [1][2] Group 1 - The company’s indirect wholly-owned subsidiary, MiRXES PTE. LTD., has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on molecular diagnostic testing and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1][2] - The memorandum is valid for 12 months from the date of signing [1] - Through this partnership, the company aims to leverage PT DIASTIKA BIOTEKINDO's existing channels to deploy blood-based microRNA or multi-omics cancer detection devices in the Indonesian market [2] Group 2 - The collaboration will allow the company to benefit from Indonesia's localization policies, such as tax incentives for local content rates of 40% [2] - The partnership is expected to provide regulatory flexibility under the ASEAN-centered medical device framework [2] - Indonesia is viewed as a pilot region for the company to replicate its business model in Southeast Asia, the Middle East, North Africa, and other regions with similar cancer profiles and healthcare structures [2]

MIRXES-B(02629)涨超8%，盘中高见47.8港元创上市新高。截至发稿，涨7.28%，报47.38港元，成交额 1413.42万港元。 消息面上，8月15日，MIRXES-B发布公告，公司的间接全资附属公司MiRXES PTE.LTD.近期已与PT DIASTIKA BIOTEKINDO(一间于印尼证券交易所上市的公司，股份代号：CHEK)(PT DIASTIKA BIOTEKINDO)订立一份谅解备忘录，据此，双方同意在印尼进行用于高发病率及高死亡率癌症早期检 测及诊断的分子诊断检测及相关仪器的注册及商业化方面进行合作。谅解备忘录期限自签署日期起计 (包括该日)为期12个月。 公告称，透过与PT DIASTIKA BIOTEKINDO合作，该集团可：透过PT DIASTIKA BIOTEKINDO现有 渠道即时透过部署基于血液的microRNA或多组学高发病率癌症(如胃癌、肺癌等)检测设备方式进军印 尼市场；利用印尼推行本地化政策(如因本地化率40%享受税务优惠)及以东盟为中心的医疗器械框架实 现监管灵活性；及利用印尼作为示范性开业地区将业务复制至东南亚、中东、北非及其他地区(该等地 区均有相似癌 ...

Group 1 - MIRXES-B (02629) has shown strong performance in the Hong Kong biotech sector, reaching a historical high of 44.98 HKD, representing a cumulative increase of over 93% since its IPO price of 23.3 HKD [1][32] - The stock has a market capitalization of 12.22 billion HKD and a trading volume of 1.16 million shares as of August 15 [1] - The stock is expected to be included in the Hong Kong Stock Connect, which has historically led to significant price increases for newly listed companies [3][4] Group 2 - MIRXES-B has a fully circulated structure, which differentiates it from traditional stocks that face lock-up periods and potential selling pressure after listing [6][7] - The company has a strong market position with its GASTROClear™ product, the only approved molecular diagnostic IVD product for gastric cancer screening globally [24][30] - The market for cancer screening in selected regions is projected to grow from 50.4 billion USD in 2023 to 82.8 billion USD by 2033, with a compound annual growth rate of 11.3% [25] Group 3 - The company has established significant technical barriers, including a sensitivity of 87% for miRNA detection, which is superior to traditional tumor markers [24][31] - The penetration rate for gastric cancer screening in high-risk populations in China has increased from 21.6% in 2019 to 27.8% in 2023, with expectations to reach 67.0% by 2033 [28] - Despite current financial performance needing improvement, the rapid development of precision medicine and the company's technical advantages suggest significant long-term potential [32]

Core Viewpoint - MiRXES-B (02629) has entered into a memorandum of understanding with PT DIASTIKA BIOTEKINDO to collaborate on the registration and commercialization of molecular diagnostic tests and related instruments for early detection and diagnosis of high-incidence and high-mortality cancers in Indonesia [1] Group 1 - The memorandum is valid for 12 months from the date of signing [1] - The collaboration allows MiRXES to leverage PT DIASTIKA BIOTEKINDO's existing channels to enter the Indonesian market with blood-based microRNA or multi-omics cancer detection devices for prevalent cancers such as gastric and lung cancer [1] - The partnership aims to utilize local policies in Indonesia, such as tax incentives for a localization rate of 40%, and regulatory flexibility under ASEAN-centered medical device frameworks [1] Group 2 - Indonesia is viewed as a pilot region for the business, with plans to replicate operations in Southeast Asia, the Middle East, North Africa, and other regions that have similar cancer profiles and healthcare structures [1]